January 9-12, 2011 in Washington, DC ~

Clinical trial safety and postmarketing pharmacovigilance is more critical than ever in the development and evaluation of the safe use of marketed medical products. This comprehensive three-day program will discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development and marketed use, how to optimally utilize epidemiological, clinical pharmacological and other techniques, risk management strategies, and how to create an effective organizational “system.” This program will focus primarily on drug products and biologics, but medical devices will have a limited role in the discussions.

(More)